| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
J Clin Oncol
|
2012
|
4.77
|
|
2
|
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
|
Mol Cancer Ther
|
2011
|
4.22
|
|
3
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
J Clin Oncol
|
2011
|
3.31
|
|
4
|
Autophagy as a target for anticancer therapy.
|
Nat Rev Clin Oncol
|
2011
|
3.19
|
|
5
|
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
|
Clin Cancer Res
|
2012
|
3.14
|
|
6
|
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
|
Cancer Res
|
2012
|
2.27
|
|
7
|
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.
|
J Thorac Oncol
|
2013
|
2.22
|
|
8
|
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
|
Am J Pathol
|
2006
|
2.07
|
|
9
|
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
|
Clin Cancer Res
|
2012
|
1.83
|
|
10
|
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
|
PLoS One
|
2011
|
1.80
|
|
11
|
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.43
|
|
12
|
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
|
Cancer
|
2011
|
1.37
|
|
13
|
PIK3CA mutations in advanced cancers: characteristics and outcomes.
|
Oncotarget
|
2012
|
1.30
|
|
14
|
A first-in-human study of conatumumab in adult patients with advanced solid tumors.
|
Clin Cancer Res
|
2010
|
1.26
|
|
15
|
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
|
Clin Cancer Res
|
2011
|
1.26
|
|
16
|
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
|
Oncotarget
|
2013
|
1.26
|
|
17
|
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.
|
Clin Cancer Res
|
2013
|
1.06
|
|
18
|
A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
|
Clin Cancer Res
|
2009
|
0.98
|
|
19
|
Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program.
|
J Clin Oncol
|
2011
|
0.97
|
|
20
|
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
|
PLoS One
|
2012
|
0.96
|
|
21
|
Neuroanatomical spatial patterns in Turner syndrome.
|
Neuroimage
|
2010
|
0.96
|
|
22
|
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
|
Oncotarget
|
2014
|
0.95
|
|
23
|
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
|
Oncotarget
|
2013
|
0.95
|
|
24
|
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.95
|
|
25
|
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
|
Oncotarget
|
2013
|
0.94
|
|
26
|
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
|
J Clin Oncol
|
2013
|
0.94
|
|
27
|
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer.
|
Mol Cancer Ther
|
2010
|
0.93
|
|
28
|
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
|
Int J Dermatol
|
2013
|
0.92
|
|
29
|
Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.
|
Curr Pharm Biotechnol
|
2014
|
0.91
|
|
30
|
Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service.
|
PLoS One
|
2012
|
0.90
|
|
31
|
Accelerator-based stereotactic radiosurgery for brainstem metastases.
|
Neurosurgery
|
2012
|
0.89
|
|
32
|
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
|
Invest New Drugs
|
2013
|
0.89
|
|
33
|
STAT3 inhibitors: finding a home in lymphoma and leukemia.
|
Oncologist
|
2014
|
0.88
|
|
34
|
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit.
|
Oncologist
|
2013
|
0.88
|
|
35
|
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
|
Mol Cancer Ther
|
2013
|
0.87
|
|
36
|
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
|
J Clin Oncol
|
2011
|
0.87
|
|
37
|
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
|
Cancer
|
2011
|
0.87
|
|
38
|
Genomic imprinting effects of the X chromosome on brain morphology.
|
J Neurosci
|
2013
|
0.86
|
|
39
|
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.
|
Mol Cancer Ther
|
2011
|
0.86
|
|
40
|
Reduced functional connectivity during working memory in Turner syndrome.
|
Cereb Cortex
|
2011
|
0.86
|
|
41
|
Contribution of executive functions to visuospatial difficulties in prepubertal girls with Turner syndrome.
|
Dev Neuropsychol
|
2011
|
0.86
|
|
42
|
Posttraumatic stress disorder following traumatic injury: narratives as unconscious indicators of psychopathology.
|
Bull Menninger Clin
|
2008
|
0.85
|
|
43
|
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
|
Mol Cancer Ther
|
2013
|
0.85
|
|
44
|
White matter aberrations in prepubertal estrogen-naive girls with monosomic Turner syndrome.
|
Cereb Cortex
|
2011
|
0.85
|
|
45
|
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
|
Cancer Chemother Pharmacol
|
2014
|
0.85
|
|
46
|
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
|
Clin Cancer Res
|
2010
|
0.84
|
|
47
|
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
|
Oncotarget
|
2014
|
0.83
|
|
48
|
Cortical brain morphology in young, estrogen-naive, and adolescent, estrogen-treated girls with Turner syndrome.
|
Cereb Cortex
|
2012
|
0.83
|
|
49
|
Aberrant parietal cortex developmental trajectories in girls with Turner syndrome and related visual-spatial cognitive development: a preliminary study.
|
Am J Med Genet B Neuropsychiatr Genet
|
2014
|
0.82
|
|
50
|
Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
|
Oncotarget
|
2014
|
0.81
|
|
51
|
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
|
Oncotarget
|
2013
|
0.80
|
|
52
|
Aberrant functional network recruitment of posterior parietal cortex in Turner syndrome.
|
Hum Brain Mapp
|
2012
|
0.80
|
|
53
|
Genomic imprinting effects on cognitive and social abilities in prepubertal girls with Turner syndrome.
|
J Clin Endocrinol Metab
|
2012
|
0.80
|
|
54
|
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
|
Invest New Drugs
|
2013
|
0.80
|
|
55
|
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib.
|
JAMA Dermatol
|
2013
|
0.79
|
|
56
|
Improving the institutional submission and approval process for clinical research protocols in oncology.
|
J Clin Oncol
|
2007
|
0.78
|
|
57
|
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.78
|
|
58
|
Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
|
J Clin Oncol
|
2011
|
0.78
|
|
59
|
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
|
Oncologist
|
2014
|
0.78
|
|
60
|
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.
|
Support Care Cancer
|
2015
|
0.77
|
|
61
|
Characteristics and survival of patients with advanced cancer and p53 mutations.
|
Oncotarget
|
2014
|
0.77
|
|
62
|
Retreatment after secondary resistance or mixed response: a pilot study.
|
Oncology
|
2013
|
0.77
|
|
63
|
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.
|
Oncologist
|
2011
|
0.77
|
|
64
|
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.76
|
|
65
|
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
|
Invest New Drugs
|
2013
|
0.76
|
|
66
|
Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases.
|
Cancer Chemother Pharmacol
|
2013
|
0.76
|
|
67
|
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.
|
Oncology
|
2016
|
0.75
|
|
68
|
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
|
Invest New Drugs
|
2014
|
0.75
|
|
69
|
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
|
JCI Insight
|
2017
|
0.75
|
|
70
|
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
|
Invest New Drugs
|
2015
|
0.75
|
|
71
|
Impact of cognitive profile on social functioning in prepubescent females with Turner syndrome.
|
Child Neuropsychol
|
2012
|
0.75
|
|
72
|
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
|
Invest New Drugs
|
2013
|
0.75
|
|
73
|
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
Target Oncol
|
2013
|
0.75
|
|
74
|
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
|
Clin Colorectal Cancer
|
2010
|
0.75
|
|
75
|
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
|
Hepatogastroenterology
|
2012
|
0.75
|
|
76
|
Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy.
|
Am J Dermatopathol
|
2014
|
0.75
|
|
77
|
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.
|
Invest New Drugs
|
2014
|
0.75
|
|
78
|
Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
|
Clin Genitourin Cancer
|
2011
|
0.75
|
|
79
|
197 Considerations in Relationship to the Approach for the Treatment of Lateralized Posterior Fossa Tumors in Children.
|
Neurosurgery
|
2016
|
0.75
|
|
80
|
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
|
Oncotarget
|
2015
|
0.75
|